Androgen receptor polyQ alleles and COVID-19 severity in men: a replication study

Background: Ample evidence indicates a sex-related difference in severity of COVID19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently desc...

ver descrição completa

Detalhes bibliográficos
Autores: López Rodríguez, Rosario, Ruiz Hornillos, Javier, Cortón, Marta, Almoguera, Berta, Mínguez, Pablo, Pérez Tomás, María Elena, Barreda Sánchez, María, Mancebo, Esther, Ondo, Lorena, Martínez Ramas, Andrea, Fernández Caballero, Lidia, Taracido Fernández, Juan Carlos, Herrero González, Antonio, Mahillo, Ignacio, Paz Artal, Estela, Guillén Navarro, Encarna, Ayuso García, María del Carmen Tomasa
Tipo de documento: artigo
Data de publicação:2022
País:España
Recursos:Universidad Autónoma de Madrid
Repositório:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglês
OAI Identifier:oai:repositorio.uam.es:10486/705606
Acesso em linha:http://hdl.handle.net/10486/705606
https://dx.doi.org/10.1111/andr.13339
Access Level:Acceso aberto
Palavra-chave:Androgen receptor
Biomarker
COVID-19
PolyQ polymorphism
Sex-related differences
Medicina
Descrição
Resumo:Background: Ample evidence indicates a sex-related difference in severity of COVID19, with less favorable outcomes observed in men. Genetic factors have been proposed as candidates to explain this difference. The polyglutamine (polyQ) polymorphism in the androgen receptor gene has been recently described as a genetic biomarker of COVID-19 severity. Objective: To test the association between the androgen receptor polyQ polymorphism and COVID-19 severity in a large cohort of COVID-19 male patients. Materials and methods: This study included 1136 male patients infected with SARSCoV-2 as confirmed by positive PCR. Patients were retrospectively and prospectively enrolled from March to November 2020. Patients were classified according to their severity into three categories: oligosymptomatic, hospitalized and severe patients requiring ventilatory support. The number of CAG repeats (polyQ polymorphism) at the androgen receptor was obtained by PCR and patients were classified as either short (<23 repeats) or long (≥23 repeats) allele carriers. The association between polyQ alleles (short or long) and COVID-19 severity was assessed by Chi-squared (Chi2) and logistic regression analysis. Results: The mean number of polyQ CAG repeats was 22 (±3). Patients were classified as oligosymptomatic (15.5%), hospitalized (63.2%), and severe patients (21.3%) requiring substantial respiratory support. PolyQ alleles distribution did not show significant differences between severity classes in our cohort (Chi2 test p > 0.05). Similar results were observed after adjusting by known risk factors such as age, comorbidities, and ethnicity (multivariate logistic regression analysis)